What we can learn from scientific talks at WCLC in order to improve clinical development
Review of new KRAS inhibitor studies including G12C and G12D
Seeing the wood from the trees in ES-SCLC developments
Part 2 of our WCLC 2023 Previews
Preview - Wwat to watch for at WCLC23
Finding rare thistles in the fields
A look at promising new approaches in SCLC
On fast followers and novel G12C combinations
Trials and tribulations associated with KRAS plus IO combos
Going beyond small molecule inhibitors to degrading various intractable targets
A rock around the KRAS clock
What can we learn from IO trials in lung cancer to help us evaluate TIGIT's prospects?
A lion roar or whimper at the prospect of KRASi plus IO trials?
Highlights from WCLC Day 1
What's hot at WCLC21?
Gems from the WCLC20 poster hall which may make an impact
A look at the exon 20 insertion landscape - all to play for!
Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?
Discussion of the Amgen sotorasib data presented at WCLC20 in Singapore
Some intriguing convergence from two recent conferences offers new insights from an AI perspective
A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies
WCLC 2019 Review – Part 3 - Targeted Therapy Highlights excluding KRASi
Summary of IO highlights and lowlights from WCLC 2019
Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials
After the WCLC2018 preview, what does the data actually teach us? A round up and commentary on 16 key trials
What to watch out for at WCLC2018 in Toronto later this month